Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diva LaboratoriesROCO:4153 +0.48%74 FCF Margin % is 2.32% as of Dec. 2025, which is 44% below its 10-year median of 4.14. GuruFocus rates ROCO:4153 with a GF Score™ of 74/100 and a GF Value™ of NT$38.03 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Diva Laboratories ranks better than 56.65% on this metric.
The historical rank and industry rank for Diva Laboratories's FCF Margin % or its related term are showing as below:
ROCO:4153'
s FCF Margin % Range Over the Past 10 Years
Min: -7.92 Med: 4.14 Max: 27.44
Current: 2.28
During the past 13 years, the highest FCF Margin % of Diva Laboratories was 27.44%. The lowest was -7.92%. And the median was 4.14%.
ROCO:4153's FCF Margin % is ranked better than 56.65% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.8
vs ROCO:4153: 2.28
Diva Laboratories FCF Margin % Related Terms
Diva Laboratories FCF Margin % Historical Data
* Premium members only.
The historical data trend for Diva Laboratories's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4153 vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Diva Laboratories's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diva Laboratories FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diva Laboratories's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Diva Laboratories's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diva Laboratories (ROCO:4153) has a FCF Margin % of 2.32% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Diva Laboratories and its competitors. This is 44% below median its historical median of 4.14. According to the industry distribution chart, Diva Laboratories ranks #88 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 43.3%.
Is Diva Laboratories' FCF Margin % too high?
Diva Laboratories' current FCF Margin % of 2.32% is 44% below median its 10-year median of 4.14. Based on the distribution chart, Diva Laboratories ranks #88 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diva Laboratories has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diva Laboratories' FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diva Laboratories ranks #88 out of 203 companies for FCF Margin %. This puts Diva Laboratories in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Diva Laboratories and its competitors. Diva Laboratories's current FCF Margin % is 2.32%, which is 44% below median its own 10-year median of 4.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diva Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Diva Laboratories (ROCO:4153) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$38.03, compared to a current price of NT$31.40 — trading 17.4% below its estimated fair value. The current FCF Margin % is 2.32%, which is 44% below median its 10-year median of 4.14. Diva Laboratories' overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Diva Laboratories (ROCO:4153), the current FCF Margin % is 2.32% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diva Laboratories (ROCO:4153) Overvalued in 2026?
Based on GuruFocus' analysis, Diva Laboratories stock appears to be undervalued.
The current stock price of NT$31.40 is trading 17.4% below its estimated GF Value™ of NT$38.03.
GuruFocus considers Diva Laboratories to be Modestly Undervalued.
Key valuation signals for ROCO:4153:
FCF Margin %: 2.32% (44% below median its 10-year median of 4.14)
GF Value™: NT$38.03 vs. price of NT$31.40 (17.4% below fair value)
No single metric tells the full story. See the ROCO:4153 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diva Laboratories Ltd is engaged in the sale, manufacturing and development of medical equipment and computer-related devices. Its products are divided into Medical display which includes radiology, endo/surgical, touch, and embedded display; and Industrial display which includes touch display monitors. It derives revenue from sale of Medical monitors, Medical parts, Industrial monitors, Industrial parts, and Parts. Geographically it operates and derives revenue from Taiwan.
74GF Score
Get the complete analysis for ROCO:4153
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4153 has been successfully added to your 
